Lab21 hires cfo
Susan Lowther joins Cambridge, UK-based firm
Lowther has spent more than 20 years in the pharmaceutical, biotech and healthcare industries and has held senior management positions at BioWisdom, RiboTargets, Lonza Biologics, Celltech and Monsanto.
Graham Mullis, Lab21 ceo, said: ‘Susan’s financial and life sciences industry expertise, particularly in the area of acquisitions, will be essential as we continue to develop the company.’
You may also like
Research & Development
AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic
The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Finance
Moderna partners with Recordati to commercialise propionic acidemia mRNA therapy
The pair have entered a strategic collaboration to advance and globally commercialise its investigational propionic acidemia treatment mRNA-3927, with Moderna leading clinical development and manufacturing and Recordati responsible for worldwide commercialisation
Finance
AstraZeneca strengthens weight management pipeline with CSPC Pharmaceuticals collaboration
The pair have signed a strategic collaboration covering eight obesity and type 2 diabetes programmes, including a clinical-ready GLP-1/GIP asset, AI-driven peptide discovery capabilities and injectable dosing technology